Initial Antiretroviral Therapy in an Integrase Inhibitor Era

• Autores: Sean G. Kelly, Mary Clare Masters, Babafemi O. Taiwo
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 33, Nº. 3, 2019 (Ejemplar dedicado a: HIV), págs. 681-692
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • With the second-generation integrase inhibitors (dolutegravir and bictegravir) extending the attributes of earlier integrase inhibitors, three-drug regimens containing integrase inhibitors plus two nucleos(t)ide reverse transcriptase inhibitors are now widely recommended for first-line (initial) treatment of human immunodeficiency virus-1 infection. Led by dolutegravir plus lamivudine, two-drug therapy is emerging as a way to reduce antiretroviral therapy cost and adverse effects without compromising treatment options should virologic failure occur. Initial two-drug therapy has limitations, including the relative incompatibility with the coemerging concept of same-day antiretroviral therapy initiation.